Immunis Rebrands to Champion a Systems Biology Approach to Aging

IRVINE, CA – June 25, 2026 – Clinical-stage biotechnology company Immunis has announced a comprehensive rebrand, unveiling a new corporate identity that reflects its ambitious mission to redefine the treatment of age-related diseases. The move comes at a pivotal moment, closely following promising interim data from a Phase 2 clinical trial of its lead biologic, IMM01-STEM, and signals a strategic pivot toward a systems-based approach to medicine.

Unlike conventional therapies that often pursue a single molecular target, Immunis is championing a new paradigm. Its platform focuses on multi-active biologics designed to influence hundreds of interconnected biological pathways simultaneously. This rebrand aligns the company’s public-facing identity with its complex, 'cell-free' science aimed at improving muscle function, metabolic health, and ultimately, human healthspan.

A New Identity for a New Paradigm

The rebranding effort goes far beyond a simple logo change. It represents a philosophical shift made tangible. The new logo, inspired by the coordinated activity of secreted signaling factors, visually represents the company's departure from the single-target mindset that has long dominated drug development. It's a visual metaphor for the intricate network of cellular communication that Immunis aims to harness.

The broader brand identity reinforces this theme, incorporating imagery centered on movement, strength, and functional independence. A refined color palette was chosen to evoke a sense of natural and warm energy, mirroring the company's vision for healthy aging. This strategic overhaul is designed to clearly communicate what sets the firm apart in a crowded biotech landscape.

“Our new brand identity captures both the biological foundation of our platform and our commitment to developing therapies that help people live stronger, healthier lives,” said Dr. Hans Keirsted, Chairman of Immunis, in a statement. He emphasized the critical role of muscle in the aging process, noting, “Muscle health is one of the most important and overlooked determinants of healthy aging. It supports physical independence, metabolic resilience, recovery from illness, and overall vitality.”

The timing is critical, as the company seeks to translate recent scientific momentum into market leadership. “As our science advances, it is critical that our brand clearly communicates what makes Immunis different,” shared Senior Scientific Communications Manager, Dr. Karissa Munoz. “This evolution aligns our visual identity with our scientific leadership and our long-term vision to redefine how age-related diseases are treated.”

The Science of the Secretome

At the heart of Immunis's platform is IMM01-STEM, a first-in-class biologic that belongs to a growing category of 'cell-free' regenerative therapies. Instead of using stem cells directly, which can carry risks such as immune rejection and complex logistical challenges, IMM01-STEM is composed of the secretome—the powerful cocktail of regenerative factors, proteins, and signaling molecules that stem cells naturally secrete to orchestrate healing and immune regulation.

This complex biologic contains hundreds of natural human factors in their physiological concentrations, allowing it to act across a wide array of signaling pathways. This multi-pronged mechanism is particularly suited for complex conditions like age-related decline, where multiple biological systems are dysregulated. Preclinical studies in mice have already demonstrated the potential of this approach, showing that IMM01-STEM increased whole-body lean mass, reduced fat, enhanced muscle fiber area, and improved grip strength and physical activity.

By delivering the therapeutic benefits of stem cell biology without the cells themselves, Immunis aims to offer a safer, more scalable solution. This 'cell-free' approach positions the company at the forefront of a major trend in regenerative medicine, moving toward more sophisticated, systems-based interventions.

Clinical Momentum Meets a Vast Unmet Need

The rebrand is anchored by significant clinical progress. Immunis recently shared positive topline interim results from its STEM-META Phase 2 study, which evaluated IMM01-STEM in obese, sarcopenic adults—a population grappling with the dual challenge of excess fat and debilitating muscle loss.

The data was highly encouraging. Subjects treated with IMM01-STEM demonstrated a preservation of muscle mass and, crucially, a significant improvement in gait speed. The treatment group saw gait speed increase by 0.16 m/s three months after treatment, a result that surpasses the 0.1 m/s threshold considered clinically meaningful for improving quality of life. Gait speed is a vital indicator of functional mobility, fall risk, and overall mortality in older adults, making this finding particularly impactful.

These results build on a previous Phase 1/2a trial that showed the therapy was safe and well-tolerated in individuals with muscle atrophy. With no FDA-approved pharmacological treatments specifically for sarcopenia, the market opportunity is substantial. Sarcopenia is estimated to affect up to 22% of seniors, a demographic projected to reach 2.1 billion globally by 2050. Market projections reflect this unmet need, with the sarcopenia treatment market expected to grow to over $5 billion by 2034. While competitors like Biophytis and TNF Pharmaceuticals are also developing therapies, Immunis’s unique multi-pathway, secretome-based biologic offers a distinct approach.

A Strategic Move for Future Growth

This rebrand is a calculated strategic move, timed to capitalize on clinical validation and solidify the company’s position for future growth. The positive data provides a powerful narrative for investors and partners, a story now amplified by a clear and compelling brand identity. This progress is backed by significant financial runway; the company secured a $25 million Series A-1 financing round in early 2025 specifically to advance its Phase 2 programs.

Looking ahead, Immunis plans to expand its manufacturing capabilities and initiate additional Phase 2 trials targeting muscle and metabolic function across multiple indications. Having already been named one of the “Top 50 Healthcare Technology Companies of 2025” by The Healthcare Technology Report, the firm is building a strong foundation for its next phase of development.

By focusing on the underlying biology of aging and the importance of muscle health, Immunis is contributing to a broader shift in medicine—one that prioritizes 'healthspan' over mere lifespan. The company’s new brand is not just a reflection of its science but a declaration of its intent to help an aging population not just live longer, but live stronger.